Dalriada Drug Discovery Inc. and SpiroChem are pleased to highlight their collaboration at Drug Discovery Chemistry 2026 in San Diego, where the teams are exhibiting together at Booth #317.

The collaboration brings together complementary expertise in medicinal chemistry and chemoproteomics to support small molecule discovery, particularly at early stages where mechanistic insight can inform compound selection and progression. By combining advanced synthetic capabilities with proteomics and mass spectrometry approaches, the teams aim to provide deeper understanding of target engagement, selectivity, and mechanism of action—contributing to early discovery decisions and target validation efforts.

SpiroChem contributes expertise in the design and synthesis of novel small molecules across diverse modalities, including challenging chemical series. Dalriada contributes specialized capabilities in chemoproteomics and mass spectrometry, enabling direct interrogation of compound–protein interactions in biologically relevant systems.

This collaboration is intended to complement broader discovery workflows and existing biology collaborations by providing targeted insight at key inflection points, helping teams better understand how compounds behave in complex biological environments.

“Combining advanced chemistry with chemoproteomics can significantly enhance our understanding of compound behavior early in discovery,” said Diana Kraskouskaya, CEO of Dalriada Drug Discovery. “SpiroChem is widely recognized for its ability to solve complex chemistry problems and generate high-quality starting points, and we see this as a highly complementary approach to supporting discovery teams working on challenging targets.”

“We see strong alignment in scientific rigor and in the value of bringing deeper mechanistic insight into discovery programs,” added Thomas Fessard, CEO of SpiroChem. “This type of collaboration allows us to extend our chemistry capabilities and platforms with targeted analytical approaches when they can make a real difference in early discovery and target validation.”

Attendees of Drug Discovery Chemistry 2026 are invited to visit Booth #317 to meet both teams and discuss how chemoproteomics-informed approaches can support early discovery and target validation.